Corpus Intelligence IC Memo — MONTEFIORE MEDICAL CENTER 2026-04-26 06:54 UTC
IC Memo — MONTEFIORE MEDICAL CENTER
Investment Committee Memorandum | NY | 1410 beds | Grade C | EBITDA uplift $221.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MONTEFIORE MEDICAL CENTER

CCN 330059 | BRONX, NY | 1410 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MONTEFIORE MEDICAL CENTER is a 1410-bed large academic medical center in BRONX, NY with $3.01B in net patient revenue and a -53.9% operating margin. The hospital serves a payer mix of 18.0% Medicare, 9.2% Medicaid, and 72.8% commercial.

Thesis: Undervalued. Our ML models identify $221.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -53.9% to -46.6% (+736bps).

Net Revenue HCRIS$3.01B
Current EBITDA COMPUTED$-1.63B
Operating Margin COMPUTED-53.9%
Occupancy HCRIS87.1%
Revenue / Bed COMPUTED$2.1M
Net-to-Gross HCRIS18.0%
Distress Probability ML42.1%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
9
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -53.9% places it below the state median. Among 9 size-comparable peers (705-2820 beds), the median margin is -12.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (705-2820), prioritizing same-state peers. 9 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MONTEFIORE MEDICAL CENTER (Target)NY1410$3.01B-53.9%
NYU LANGONE HOSPITALSNY1618$7.24B-7.8%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
MOUNT SINAI HOSPITALNY1085$3.20B-12.1%
LONG ISLAND JEWISH MEDICAL CENNY1161$2.97B-27.0%
NORTH SHORE UNIVERSITY HOSPITANY782$2.27B-50.0%
STONY BROOK UNIVERSITY HOSPITANY725$1.90B-4.9%
KALEIDA HEALTHNY954$1.38B-8.8%
ALBANY MEDICAL CENTER HOSPITALNY719$1.11B-19.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $221.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$63.3M+210bp18mo
Cost to Collect4.5%2.5%$60.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$59.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$36.7M+122bp9mo
Clean Claim Rate88.0%96.0%$1.9M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$63.3M
Cost to Collect
$60.3M
Denial Rate Reduction
$59.7M
A/R Days Reduction
$36.7M
Clean Claim Rate
$1.9M
Total EBITDA Uplift$221.8M
Current EBITDA$-1.63B
+ RCM Uplift+$221.8M
Pro Forma EBITDA$-1.40B
Current Margin-53.9%
Pro Forma Margin-46.6%
WC Released (1x)$115.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.50B$-8.50B0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.50B$-10.17B0.00x-100.0%
Bull Case9.0x11.0x$-2.25B$-10.25B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.25B$-11.84B0.00x-100.0%
Bear Case11.0x10.0x$-2.75B$-8.80B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.75B$-10.57B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 9 hospitals with 705-2820 beds
  • Same-state prioritization (n=10)
  • Comp margins: P25=-27.0% / P50=-12.1% / P75=-7.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.